Form 8-K Travere Therapeutics, For: Sep 26
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- SpaceX shares fall as second lockup period ends
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
Travere Therapeutics (TVTX) PT Raised to $18 at Barclays
September 30, 2024 6:13 AM EDTBarclays analyst Carter Gould raised the price target on Travere Therapeutics (NASDAQ: TVTX) to $18.00 (from $14.00) while maintaining a Overweight rating.
The analyst comments "Forthcoming FSGS updates should provide steady set of catalysts de-risking regulatory path (adding $300mn+ to U.S. peak sales potential, and... More
Travere Therapeutics (TVTX) PT Lowered to $19 at Citi
September 27, 2024 7:23 AM EDTCiti analyst Carly Kenselaar lowered the price target on Travere Therapeutics (NASDAQ: TVTX) to $19.00 (from $23.00) while maintaining a Buy rating.
The analyst comments "The enrollment pause in the Ph3 HCU trial triggered by the pegtibatinase manufacturing scale-up not meeting required specs is obviously... More
